A Study Evaluating MM-310 in Patients With Solid Tumors

ClinicalTrials.gov ID: NCT03076372

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03076372. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.

Study identification

NCT ID: NCT03076372
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Merrimack Pharmaceuticals; Industry
Enrollment: 34 participants

Conditions and interventions

Conditions

Interventions

MM-310 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 22, 2017 (Actual)
Primary completion: Jun 2018 (Estimated)
Completion: Dec 2018 (Estimated)
Last update posted: Feb 27, 2018

2017 – 2018

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
Honor Health	Scottsdale	Arizona	85259	Recruiting
University California San Francisco	San Francisco	California	94143	Recruiting
Mayo Clinic	Rochester	Minnesota	55902	Recruiting
Roswell Park Cancer Institute	Buffalo	New York	14263	Recruiting
Duke University	Durham	North Carolina	27710	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03076372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 27, 2018 · Synced Nov 15, 2026